Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Posted: August 14, 2024 at 2:37 am

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs

Read the rest here:
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Related Posts